K+S Aktiengesellschaft (ETR:SDF) | WebDisclosure

Basculer en Français

10815	Companies
234337	Keywords
163119	Articles
125305	Press releases

Headlines Articles Press releases K+S Aktiengesellschaft

Home
Companies
K+S Aktiengesellschaft

PRESS RELEASE

published on 10/23/2024 at 10:51, 1 year 9 months ago

EQS-Adhoc: K+S Aktiengesellschaft: Change of Chairmanship on the BoED of K+S: Dr. Burkhard Lohr hands over Chairmanship of the BoED to Dr. Christian H. Meyer (CFO) in May 2025
Dr. Burkhard Lohr to retire as Chairman of the Board of Executive Directors at K+S Aktiengesellschaft, with Dr. Christian H. Meyer set to take over in June 2025

Chairmanship Retirement K+S Aktiengesellschaft Dr. Burkhard Lohr Dr. Christian H. Meyer
BRIEF

published on 04/30/2024 at 10:23, 2 years 3 months ago

K+S Aktiengesellschaft annonce une hausse de ses résultats financiers au premier trimestre 2024 et maintient ses prévisions annuelles

Performance Financière Attentes Du Marché T1 2024 Prévisions Annuelles K+S Aktiengesellschaft
BRIEF

published on 04/30/2024 at 10:23, 2 years 3 months ago

K+S Aktiengesellschaft Reports Surge in Q1 2024 Financial Results, Maintains Annual Forecast

Financial Performance Q1 2024 Market Expectations Annual Forecast K+S Aktiengesellschaft
PRESS RELEASE

published on 04/30/2024 at 10:18, 2 years 3 months ago

EQS-Adhoc: K+S Aktiengesellschaft: EBITDA and adjusted free cash flow in the first quarter of 2024 significantly above market expectations; Forecast for the full year 2024 unchanged
K+S Aktiengesellschaft reports significantly higher EBITDA and adjusted free cash flow in Q1 2024, exceeding market expectations. Full year 2024 forecast remains unchanged

EBITDA Forecast Free Cash Flow Q1 2024 K+S Aktiengesellschaft
PRESS RELEASE

published on 07/26/2023 at 16:22, 3 years ago

EQS-Adhoc: K+S Aktiengesellschaft: Quarter Results / Forecast
PRESS RELEASE

published on 06/14/2023 at 11:51, 3 years 1 month ago

EQS-Adhoc: K+S Aktiengesellschaft: Achievability of forecast key figure ranges unlikely due to recent potash price movements
PRESS RELEASE

published on 03/14/2023 at 14:37, 3 years 4 months ago

EQS-Adhoc: K+S Aktiengesellschaft: K+S resolves to return capital to shareholders of up to a total of EUR 391.4 million or about EUR 2 per share (Vara consensus estimate: EUR 1.50 per share)

Accesswire

Published on 08/10/2026 at 08:00, 2 hours 33 minutes ago

Galantas Gold Expands Indiana Drill Program to 12,500 Metres
Published on 08/10/2026 at 08:00, 2 hours 33 minutes ago

Results of AGM and Management Update Presentation
Published on 08/08/2026 at 00:00, 2 days 10 hours ago

Boron One Announces Change of Auditor
Published on 08/07/2026 at 23:15, 2 days 11 hours ago

Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days 11 hours ago

Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing

View all ACCESSWIRE

EQS Group

Published on 08/10/2026 at 10:12, 21 minutes ago

Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 08/10/2026 at 10:10, 23 minutes ago

Hana Bank Subsidiary GLN Expands QR Payment Network for International Travelers to Korea
Published on 08/10/2026 at 09:50, 43 minutes ago

Photon Energy N.V. Bond 21/27 (ISIN: DE000A3KWKY4): Signs of a crisis are mounting. What can investors do? Invitation to video conferences (German/English)
Published on 08/10/2026 at 09:00, 1 hour 33 minutes ago

Original-Research: Rosenbauer International AG (von NuWays AG): BUY
Published on 08/10/2026 at 09:00, 1 hour 33 minutes ago

Original-Research: Bittium Oyj (von NuWays AG): BUY

Les Echos

Published on 08/10/2026 at 09:47, 46 minutes ago

260810 BENETEAU Transactions sur actions propres
Published on 08/10/2026 at 09:22, 1 hour 11 minutes ago

Number of shares and voting rights - July 2026 (In French only)
Published on 08/10/2026 at 09:22, 1 hour 11 minutes ago

Nombre total d'actions et droits de vote - juillet 2026
Published on 08/10/2026 at 07:00, 3 hours 33 minutes ago

BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Published on 08/10/2026 at 07:00, 3 hours 33 minutes ago

Biophytis annonce l’autorisation de l’étude clinique OBA au Brésil et partage les perspectives de BIO101 dans l’obésité

View all LES ECHOS COMFI WIRE